Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Additionally we are shipping Sclerostin Kits (54) and Sclerostin Proteins (18) and many more products for this protein.
Showing 10 out of 101 products:
Human Polyclonal Sclerostin Primary Antibody for IHC (p), WB - ABIN390193
Semenov, He: LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. in The Journal of biological chemistry 2006
Show all 2 references for 390193
Human Polyclonal Sclerostin Primary Antibody for EIA, IHC (p) - ABIN358751
Ellies, Viviano, McCarthy, Rey, Itasaki, Saunders, Krumlauf: Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2006
Show all 2 references for 358751
SOST is frequently expressed in skeletal bone- and cartilage-forming tumors. The strong spatial correlation with bone formation and the in vitro expression patterns are in line with the known functions of SOST in nonneoplastic bone, as a feedback inhibitor on osteogenic differentiation.
Intermittent compressive stress regulates Notch (show NOTCH1 Antibodies) receptor and target gene expression via the TGF-beta (show TGFB1 Antibodies) signaling pathway. Notch (show NOTCH1 Antibodies) signaling participates in TGF-beta (show TGFB1 Antibodies)-induced sclerostin expression in periodontal ligament cells.
Dickkopf-1 (show DKK1 Antibodies) and sclerostin were never correlated with each other or with bone turnover markers patients with Paget's disease of bone. Sclerostin was positively correlated with age.
These data suggest that sclerostin plays an important role in the bone remodeling of tooth movement.
Circulating sclerostin and Dickkopf-1 (show DKK1 Antibodies) levels do not change across the menstrual cycle and do not demonstrate any relationship with estradiol in premenopausal women.
SOST is expressed in the aorta and downregulated in human aortic aneurysms and atheros (show WNT2 Antibodies)clerosis, possibly because of epigenetic silencing.
The level of sclerostin was higher in the female obstructive sleep apnea (OSA) patients than that in female controls. Further, in OSA women with cardiovascular comorbidities, sclerostin was higher than in women without such comorbidities. In men, there were no differences in the serum sclerostin level between the OSA and control subjects, nor was there any relationship with cardiovascular diseases.
Knockdown of SOST in MG-63 cells increases osteogenesis and ratio of OPG/RANKL (show TNFSF11 Antibodies) in vitro
The findings confirm that the human SOST gene and sclerostin expression can be considered to be directly 1,25-dihydroxyvitamin D-responsive in osteocytes.
Our study highlighted the high serum levels of DKK-1 (show DKK1 Antibodies) and sclerostin in T1DM children and their relationship with altered glycemic control
In mice, sclerostin deficiency hastened reparative dentinogenesis after pulp injury, suggesting that the inhibition of sclerostin may constitute a promising therapeutic strategy for improving the healing of damaged pulps.
Sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis via wnt (show WNT2 Antibodies) signaling pathway inhibition.
Analysis of SOST expression using large minigenes reveals the MEF2C (show MEF2C Antibodies) binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D3 or TGFbeta1 (show TGFB1 Antibodies) responsiveness.
removal of sclerostin appears to modestly protect the alveolar bone from resorption in this experimental setting
chronic TNFalpha (tumor necrosis factor alpha (show TNF Antibodies))-dependent arthritis, fibroblast-like synoviocytes constitute a major source of sclerostin and that either the lack of sclerostin or its antibody-mediated inhibition leads to an acceleration of rheumatoid arthritis (RA)-like disease.
Data show that the phenotype of Notch (show NOTCH1 Antibodies) activation in osteocytes was prevented in matrix protein 1 (Dmp1 (show DMP1 Antibodies))-Cre;Rosa(Notch (show NOTCH1 Antibodies)) mice hemizygous for the Dmp1 (show DMP1 Antibodies)-sclerostin (SOST) transgene.
Results found that sclerostin enhances adipocyte differentiation in 3T3-L1 cells and reduced TAZ (show TAZ Antibodies)-responsive transcriptional activity and TAZ (show TAZ Antibodies)-responsive gene expression, indicating a role for TAZ (show TAZ Antibodies) as a regulator of adipogenesis by sclerostin.
Our results suggested that sclerostin could be expressed in the liver and sustained successfully at high levels in the blood by using the PhiC31 integrase system, leading to trabecular bone loss.
Sclerostin depletion enhances tibial fracture healing.
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.